Literature DB >> 18724071

Biological approaches to therapy of pancreatic cancer.

Han Hsi Wong1, Nicholas R Lemoine.   

Abstract

Pancreatic cancer is a lethal disease and notoriously difficult to treat. Only a small proportion is curative by surgical resection, whilst standard chemotherapy for patients with advanced disease has only modest effect with substantial toxicity. Clearly there is a need for the continual development of novel therapeutic agents to improve the current situation. Improvement of our understanding of the disease has generated a large number of studies on biological approaches targeting the molecular abnormalities of pancreatic cancer, including gene therapy and signal transduction inhibition, antiangiogenic and matrix metalloproteinase inhibition, oncolytic viral therapy and immunotherapy. This article provides a review of these approaches, both investigated in the laboratories and in subsequent clinical trials. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724071      PMCID: PMC2882228          DOI: 10.1159/000151536

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  323 in total

1.  Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors.

Authors:  K Satoh; K Kaneko; M Hirota; A Masamune; A Satoh; T Shimosegawa
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

2.  In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer.

Authors:  D Evoy; E A Hirschowitz; H A Naama; X K Li; R G Crystal; J M Daly; M D Lieberman
Journal:  J Surg Res       Date:  1997-04       Impact factor: 2.192

3.  Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.

Authors:  A Block; S H Chen; K Kosai; M Finegold; S L Woo
Journal:  Pancreas       Date:  1997-07       Impact factor: 3.327

Review 4.  Innovative treatments for pancreatic cancer.

Authors:  S M Lieberman; H Hörig; H L Kaufman
Journal:  Surg Clin North Am       Date:  2001-06       Impact factor: 2.741

5.  Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

Authors:  S R Bramhall; A Rosemurgy; P D Brown; C Bowry; J A Buckels
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

6.  Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer.

Authors:  H Kasuya; Y Nishiyama; S Nomoto; J Hosono; S Takeda; A Nakao
Journal:  J Surg Oncol       Date:  1999-11       Impact factor: 3.454

7.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Authors:  J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

Review 8.  Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.

Authors:  D Kirn
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

9.  Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer.

Authors:  M Kobari; S Egawa; K Shibuya; M Sunamura; K Saitoh; S Matsuno
Journal:  Br J Surg       Date:  2000-01       Impact factor: 6.939

10.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.

Authors:  Sarah P Thayer; Marina Pasca di Magliano; Patrick W Heiser; Corinne M Nielsen; Drucilla J Roberts; Gregory Y Lauwers; Yan Ping Qi; Stephan Gysin; Carlos Fernández-del Castillo; Vijay Yajnik; Bozena Antoniu; Martin McMahon; Andrew L Warshaw; Matthias Hebrok
Journal:  Nature       Date:  2003-09-14       Impact factor: 49.962

View more
  12 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation.

Authors:  Jian Du; Jingwen Wang; Guang Tan; Zhengang Cai; Lu Zhang; Bo Tang; Zhongyu Wang
Journal:  Med Oncol       Date:  2012-02-07       Impact factor: 3.064

3.  Novel therapies for pancreatic cancer: setbacks and progress.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Future Oncol       Date:  2010-07       Impact factor: 3.404

4.  Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China.

Authors:  Yong Chen; JiHui Hao; WeiDong Ma; Yong Tang; ChunTao Gao; XiShan Hao
Journal:  J Gastrointest Surg       Date:  2011-04-12       Impact factor: 3.452

5.  Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.

Authors:  Lihong Zhang; Wei Zhu; Jiali Li; Xuejing Yang; Yanjie Ren; Jingxiu Niu; Yan Pang
Journal:  Mol Clin Oncol       Date:  2015-10-23

Review 6.  Targeted drug delivery in pancreatic cancer.

Authors:  Xianjun Yu; Yuqing Zhang; Changyi Chen; Qizhi Yao; Min Li
Journal:  Biochim Biophys Acta       Date:  2009-10-22

Review 7.  Gene therapy in pancreatic cancer.

Authors:  Si-Xue Liu; Zhong-Sheng Xia; Ying-Qiang Zhong
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

8.  Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.

Authors:  Han Hsi Wong; Guozhong Jiang; Rathi Gangeswaran; Pengju Wang; Jiwei Wang; Ming Yuan; Hexiao Wang; Vipul Bhakta; Heike Müller; Nicholas R Lemoine; Yaohe Wang
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

9.  hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.

Authors:  Else M Inderberg Suso; Svein Dueland; Anne-Marie Rasmussen; Turid Vetrhus; Steinar Aamdal; Gunnar Kvalheim; Gustav Gaudernack
Journal:  Cancer Immunol Immunother       Date:  2011-03-02       Impact factor: 6.968

10.  Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Dorris Quon; William C Blackwelder; Erlinda M Gordon; Frederick L Hall
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.